The combination of exposure-response and case-control analyses in regulatory decision making

Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2013, Pages 160-166

  Yang, Jun ^a   Zhao, Hong ^a   Garnett, Christine ^a   Rahman, Atiqur ^a   Gobburu, Jogarao V ^a   Pierce, William ^a   Schechter, Genevieve ^a   Summers, Jeffery ^a   Keegan, Patricia ^a   Booth, Brian ^a   Wang, Yaning ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Case control; Confounding; Exposure response; Oncology; Regulatory scientific affairs

Indexed keywords

TRASTUZUMAB;

ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; DRUG DOSE REGIMEN; EXPOSURE RESPONSE ANALYSIS; HUMAN; OVERALL SURVIVAL; STOMACH CANCER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DECISION MAKING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KAPLAN-MEIER ESTIMATE; STOMACH NEOPLASMS;

EID: 84877865099     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012445206     Document Type: Article

References (15)

1. Roy A, Mould DR, Wang XF, et al. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol . 2007;47: 1408-1420.
2. Mould DR, Zhang X, Nieforth K, et al. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatmentexperienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther . 2005;77:515-528.
3. Friberg LE, de Greef R, Kerbusch T, et al. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther . 2009;86:84-91.
4. Dayde D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood . 2009;113:3765-3772.
5. Roy A, Zhu H, Cohen M, et al. Analysis of ixabepilone exposureresponse for neutropenia in patients with metastatic breast cancer. J Clin Oncol . 2008;26(suppl). Abstract 2511.
6. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J . 2005;7:E503-E512.
7. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med . 1998;17:2265-2281.
8. Australian public assessment report for trastuzumab. http://www .tga.gov.au/pdf/auspar/auspar-herceptin.pdf
9. Assessment report for herceptin. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Assessment-Report-Variation/human/000278/WC500074921.pdf
10. Therneau TM, Atkinson EJ. An Introduction to Recursive Partitioning: Using the RPART Routines . Technical Report 61. Rochester, MN: Mayo Clinic, Section of Statistics; 1997.
11. Herceptin product label. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2010/103792s5256lbl.pdf
12. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med . 1998;338(8):499-505.
13. Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat . 2007;17(1):1-13.
14. Zhu H, Wang Y. Evaluation of false positive rate based on exposure-response analyses for two compounds in fixed-dose combination products. J Pharmacokinet Pharmacodyn . 2011;38(6):671-696.
15. Kim J, Sun CL, Mailey B, et al. Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol . 2010;21(1):152-160.